Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (341-350 of 442) with videos related to

Pageof 45
Sort By:
NPJ Breast Cancer|October 2, 2024
Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironmentDaniel C Stewart, Becky K Brisson, Bassil Dekky, et al.
JCO Precision Oncology|June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceLorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
The Journal of Liquid Biopsy|June 16, 2025
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumorsNicola Fusco, Konstantinos Venetis, Francesco Pepe, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
JCO Precision Oncology|June 17, 2021
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast CancerLorenzo Gerratana, Andrew A Davis, Qiang Zhang, et al.
Breast Cancer Research : BCR|September 17, 2014
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic disseminationMario Giuliano, Antonio Giordano, Summer Jackson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Breast Cancer Research and Treatment|June 21, 2013
Inflammatory breast cancer (IBC): clues for targeted therapiesSandra V Fernandez, Fredika M Robertson, Jianming Pei, et al.
Pageof 45

Showing results (341-350 of 442) with videos related to

Sort By:
Pageof 45
NPJ Breast Cancer|October 2, 2024
Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironmentDaniel C Stewart, Becky K Brisson, Bassil Dekky, et al.
JCO Precision Oncology|June 30, 2022
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's ExperienceLorenzo Gerratana, Michael Movarek, Firas Wehbe, et al.
The Journal of Liquid Biopsy|June 16, 2025
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumorsNicola Fusco, Konstantinos Venetis, Francesco Pepe, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
JCO Precision Oncology|June 17, 2021
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast CancerLorenzo Gerratana, Andrew A Davis, Qiang Zhang, et al.
Breast Cancer Research : BCR|September 17, 2014
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic disseminationMario Giuliano, Antonio Giordano, Summer Jackson, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Breast Cancer Research and Treatment|June 21, 2013
Inflammatory breast cancer (IBC): clues for targeted therapiesSandra V Fernandez, Fredika M Robertson, Jianming Pei, et al.
Pageof 45